NCT03797625View on ClinicalTrials.gov

Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

May 4, 2017

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2021

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Irinotecan

60mg/m2，D1，8

DRUG

DDP

60mg/m2，D1

DRUG

Endostar

15mg/d，d1-d7 civ

Trial Locations (1)

200032

Cancer hospital Fudan University, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT03797625 - Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas | Biotech Hunter | Biotech Hunter